

## Special Issue

# Partial Breast Radiotherapy: Evidence and Challenges

### Message from the Guest Editor

Guidelines from GEC-ESTRO, ASTRO and ABS defined patients to whom the following could be safely reduced: (a) the breast volume irradiated, (b) the treatment time, and (c) unnecessary radiation exposure to healthy tissues. For these reasons, the concept of accelerated partial breast irradiation (APBI) in early breast cancer after BCS has gained acceptance. There are several radiation techniques for APBI. Brachytherapy, external beam radiotherapy, and IORT are accepted APBI techniques following data provided by phase III trials. Non-inferior results in terms of local control and suggested improved toxicity encourage APBI treatment worldwide. The aim of the present Special Issue is to shed light on the challenges in APBI treatment, including non-cancer death rates, biological and immunological effects of tumor bed irradiation, and combination with other cancer treatments.

### Guest Editor

Dr. Pedro Carlos Lara

Comprehensive Cancer Center, San Roque University Hospital,  
Fernando Pessoa Canarias University, Las Palmas de Gran Canaria,  
Spain

### Deadline for manuscript submissions

closed (31 March 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/184191](https://mdpi.com/si/184191)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)